Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency

Journal of Immunology

Volumn 190, Issue 7, 2013, Pages 3732-3739

  Bates, John T ^a,b   Keefer, Christopher J ^a,b,d   Utley, Thomas J ^b   Correia, Bruno E ^c   Schief, William R ^c   Crowe, James E ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FAB19; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SOMATIC MUTATION; VIRUS NEUTRALIZATION;

EID: 84875443232     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202964     Document Type: Article

References (52)

1. Hacking, D., and J. Hull. 2002. Respiratory syncytial virus - viral biology and the host response. J. Infect. 45: 18-24.
2. Handforth, J., J. S. Friedland, and M. Sharland. 2000. Basic epidemiology and immunopathology of RSV in children. Paediatr. Respir. Rev. 1: 210-214.
3. Domachowske, J. B., and H. F. Rosenberg. 1999. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin. Microbiol. Rev. 12: 298-309.
4. The IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537.
5. Groothuis, J. R., and H. Nishida. 2002. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr. Int. 44: 235-241.
6. Top, F. H., Jr., E. M. Connor, and D. A. Carlin. 2000. Prophylaxis against respiratory syncytial virus in premature infants: IMpact-RSV Study Group. Lancet 355: 1014.
7. Crowe, J. E., C. Y. Firestone, R. Crim, J. A. Beeler, K. L. Coelingh, C. F. Barbas, D. R. Burton, R. M. Chanock, and B. R. Murphy. 1998. Monoclonal antibodyresistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 252: 373-375.
8. Crowe, J. E., Jr., B. R. Murphy, R. M. Chanock, R. A.Williamson, C. F. Barbas, III, and D. R. Burton. 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl. Acad. Sci. USA 91: 1386-1390.
9. Brandenburg, A. H., J. Groen,H. A. van Steensel-Moll, E. C. Claas, P. H. Rothbarth, H. J. Neijens, and A. D. Osterhaus. 1997. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J. Med. Virol. 52: 97-104.
10. Weitkamp, J. H., B. J. Lafleur, H. B. Greenberg, and J. E. Crowe, Jr. 2005. Natural evolution of a human virus-specific antibody gene repertoire by somatic hypermutation requires both hotspot-directed and randomly-directed processes. Hum. Immunol. 66: 666-676.
11. Weitkamp, J. H., N. Kallewaard, K. Kusuhara, E. Bures, J. V. Williams, B. LaFleur, H. B. Greenberg, and J. E. Crowe, Jr. 2003. Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires. J. Immunol. 171: 4680-4688.
12. Rani, M., M. Bolles, E. F. Donaldson, T. Van Blarcom, R. Baric, B. Iverson, and G. Georgiou. 2012. Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus. J. Virol. 86: 9113-9121.
13. Wang, Y., Z. Y. Keck, A. Saha, J. Xia, F. Conrad, J. Lou, M. Eckart, J. D. Marks, and S. K. Foung. 2011. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J. Biol. Chem. 286: 44218-44233.
14. Gustchina, E., M. Li, J. M. Louis, D. E. Anderson, J. Lloyd, C. Frisch, C. A. Bewley, A. Gustchina, A. Wlodawer, and G. M. Clore. 2010. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog. 6: e1001182.
15. Gustchina, E., J. M. Louis, C. Frisch, F. Ylera, A. Lechner, C. A. Bewley, and G. M. Clore. 2009. Affinity maturation by targeted diversification of the CDRH2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology 393: 112-119.
16. Steckbeck, J. D., I. Orlov, A. Chow, H. Grieser, K.Miller, J. Bruno, J. E. Robinson, R. C. Montelaro, and K. S. Cole. 2005. Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J. Virol. 79: 12311-12320.
17. Nelson, C. D., L. M. Palermo, S. L. Hafenstein, and C. R. Parrish. 2007. Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies. Virology 361: 283-293.
18. De Genst, E., F. Handelberg, A. Van Meirhaeghe, S. Vynck, R. Loris, L. Wyns, and S. Muyldermans. 2004. Chemical basis for the affinity maturation of a camel single domain antibody. J. Biol. Chem. 279: 53593-53601.
19. England, P., R. Nageotte, M. Renard, A. L. Page, and H. Bedouelle. 1999. Functional characterization of the somatic hypermutation process leading to antibody D1.3, a high affinity antibody directed against lysozyme. J. Immunol. 162: 2129-2136.
20. Lavoie, T. B., W. N. Drohan, and S. J. Smith-Gill. 1992. Experimental analysis by site-directed mutagenesis of somatic mutation effects on affinity and fine specificity in antibodies specific for lysozyme. J. Immunol. 148: 503-513.
21. Lavoie, T. B., S. Mohan, C. A. Lipschultz, J. C. Grivel, Y. Li, C. R. Mainhart, L. N. Kam-Morgan, W. N. Drohan, and S. J. Smith-Gill. 1999. Structural differences among monoclonal antibodies with distinct fine specificities and kinetic properties. Mol. Immunol. 36: 1189-1205.
22. Sagawa, T., M. Oda, M. Ishimura, K. Furukawa, and T. Azuma. 2003. Thermodynamic and kinetic aspects of antibody evolution during the immune response to hapten. Mol. Immunol. 39: 801-808.
23. Altobelli, G., and S. Subramaniam. 2000. Kinetics of association of anti-lysozyme monoclonal antibody D44.1 and hen-egg lysozyme. Biophys. J. 79: 2954-2965.
24. Goldbaum, F. A., A. Cauerhff, C. A. Velikovsky, A. S. Llera, M. M. Riottot, and R. J. Poljak. 1999. Lack of significant differences in association rates and affinities of antibodies from short-term and long-term responses to hen egg lysozyme. J. Immunol. 162: 6040-6045.
25. Furukawa, K., A. Manabe, A. Furukawa, H. Kuba, T. Okajima, and T. Azuma. 2006. Initial repertoire of anti-(4-hydroxy-3-nitrophenylacetyl) antibodies as potential donors for effective affinity maturation. Mol. Immunol. 43: 1751-1760.
26. Xavier, K. A., and R. C. Willson. 1998. Association and dissociation kinetics of anti-hen egg lysozyme monoclonal antibodies HyHEL-5 and HyHEL-10. Biophys. J. 74: 2036-2045.
27. Weitkamp, J. H., N. Kallewaard, K. Kusuhara, D. Feigelstock, N. Feng, H. B. Greenberg, and J. E. Crowe, Jr. 2003. Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. J. Immunol. Methods 275: 223-237.
28. Ruiz, M., V. Giudicelli, C. Ginestoux, P. Stoehr, J. Robinson, J. Bodmer, S. G. Marsh, R. Bontrop, M. Lemaitre, G. Lefranc, et al. 2000. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 28: 219-221.
29. Brock, S. C., J. M. Heck, P. A. McGraw, and J. E. Crowe, Jr. 2005. The transmembrane domain of the respiratory syncytial virus F protein is an orientationindependent apical plasma membrane sorting sequence. J. Virol. 79: 12528-12535.
30. Murphy, B. R., A. V. Sotnikov, L. A. Lawrence, S. M. Banks, and G. A. Prince. 1990. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8: 497-502.
31. Altschul, S. F., T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25: 3389-3402.
32. Das, R., and D. Baker. 2008. Macromolecular modeling with rosetta. Annu. Rev. Biochem. 77: 363-382.
33. Wang, C., P. Bradley, and D. Baker. 2007. Protein-protein docking with backbone flexibility. J. Mol. Biol. 373: 503-519.
34. McLellan, J. S., M. Chen, A. Kim, Y. Yang, B. S. Graham, and P. D. Kwong. 2010. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol. 17: 248-250.
35. Fleishman, S. J., A. Leaver-Fay, J. E. Corn, E. M. Strauch, S. D. Khare, N. Koga, J. Ashworth, P. Murphy, F. Richter, G. Lemmon, et al. 2011. RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. PLoS ONE 6: e20161.
36. Gray, J. J., S. Moughon, C. Wang, O. Schueler-Furman, B. Kuhlman, C. A. Rohl, and D. Baker. 2003. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J. Mol. Biol. 331: 281-299.
37. Smith, C. A., and T. Kortemme. 2008. Backrub-like backbone simulation recapitulates natural protein conformational variability and improves mutant sidechain prediction. J. Mol. Biol. 380: 742-756.
38. DeLano, W. L. 2002. The PyMOL Molecular Graphics System. Delano Scientific, Palo Alto, CA.
39. Wu, H., D. S. Pfarr, Y. Tang, L. L. An, N. K. Patel, J. D. Watkins, W. D. Huse, P. A. Kiener, and J. F. Young. 2005. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350: 126-144.
40. Foote, J., and C. Milstein. 1991. Kinetic maturation of an immune response. Nature 352: 530-532.
41. Burton, D. R. 2002. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2: 706-713.
42. Kalinke, U., E. M. Bucher, B. Ernst, A. Oxenius, H. P. Roost, S. Geley, R. Kofler, R. M. Zinkernagel, and H. Hengartner. 1996. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity 5: 639-652.
43. Burton, D.R.,R.C.Desrosiers,R. W.Doms,W. C. Koff, P. D.Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5: 233-236.
44. Parren, P. W., J. P. Moore, D. R. Burton, and Q. J. Sattentau. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 (Suppl. A): S137-S162.
45. Saphire, E. O., M. Montero, A. Menendez, N. E. van Houten, M. B. Irving, R. Pantophlet, M. B. Zwick, P. W. Parren, D. R. Burton, J. K. Scott, and I. A. Wilson. 2007. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 crossreactive antibodies. J. Mol. Biol. 369: 696-709.
46. Burton, D. R., R. L. Stanfield, and I. A. Wilson. 2005. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102: 14943-14948.
47. Kallewaard, N. L.,B. A.McKinney, Y. Gu,A. Chen, B. V. Prasad, and J. E. Crowe, Jr. 2008. Functional maturation of the human antibody response to rotavirus. J. Immunol. 180: 3980-3989.
48. Desmyter, A., K. Decanniere, S. Muyldermans, and L. Wyns. 2001. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. 276: 26285-26290.
49. Mizutani, R., K. Miura, T. Nakayama, I. Shimada, Y. Arata, and Y. Satow. 1995. Three-dimensional structures of the Fab fragment of murine N1G9 antibody from the primary immune response and of its complex with (4-hydroxy-3- nitrophenyl)acetate. J. Mol. Biol. 254: 208-222.
50. Gimenez, H. B., S. Chisholm, J. Dornan, and P. Cash. 1996. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin. Diagn. Lab. Immunol. 3: 280-286.
51. Anderson, L. J., and C. A. Heilman. 1995. Protective and disease-enhancing immune responses to respiratory syncytial virus. J. Infect. Dis. 171: 1-7.
52. Mastelic, B., A. T. Kamath, P. Fontannaz, C. Tougne, A. F. Rochat, E. Belnoue, C. Combescure, F. Auderset, P. H. Lambert, F. Tacchini-Cottier, and C. A. Siegrist. 2012. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J. Immunol. 189: 5764-5772.